[{"AccountsPayableCurrent_0_Q1_USD":9122000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q1_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q1_USD":0.0,"OtherAssetsNoncurrent_0_Q1_USD":13415000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":3231000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":9252000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":8685000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":1886000.0,"OperatingIncomeLoss_1_Q1_USD":-57322000.0,"NumberOfReportableSegments_1_Q1_segment":1.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":1248000.0,"NumberOfOperatingSegments_1_Q1_segment":1.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-113177000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-74391000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":4135000.0,"MarketableSecuritiesCurrent_0_Q1_USD":84826000.0,"LiabilitiesCurrent_0_Q1_USD":307570000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":727770000.0,"Liabilities_0_Q1_USD":1127396000.0,"InvestmentIncomeInterest_1_Q1_USD":78000.0,"InventoryWorkInProcessNetOfReserves_0_Q1_USD":1883000.0,"NetIncomeLoss_1_Q1_USD":-61660000.0,"InventoryRawMaterialsNetOfReserves_0_Q1_USD":1321000.0,"OtherNoncashIncomeExpense_1_Q1_USD":0.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":0.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":4252000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_1_Q1_shares":436573.0,"StockholdersEquity_0_Q1_USD":-399626000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q1_shares":8613006.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q1_shares":8613006.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1_Q1_shares":892157.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1_Q1_shares":135909.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q1_shares":5308419.0,"ShareBasedCompensation_1_Q1_USD":11262000.0,"PaymentsToAcquireMarketableSecurities_1_Q1_USD":78426000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":61212000.0,"RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_1_Q1_USD":29509000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1107808000.0,"RestrictedCash_0_Q1_USD":9087000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":30880000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":2968000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":4135000.0,"ProceedsFromRelatedPartyDebt_1_Q1_USD":0.0,"ProceedsFromCollaborators_1_Q1_USD":0.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":17569000.0,"Revenues_1_Q1_USD":41063000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":91637151.0,"InventoryNet_0_Q1_USD":4172000.0,"InterestExpense_1_Q1_USD":3505000.0,"CommonStockValue_0_Q1_USD":2000.0,"CommonStockSharesOutstanding_0_Q1_shares":91942643.0,"CommonStockSharesIssued_0_Q1_shares":91942643.0,"CommonStockSharesAuthorized_0_Q1_shares":564111242.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0,"CommitmentsAndContingencies_0_Q1_USD":null,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-183433000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":494047000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q1_USD":569800000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-61660000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":484960000.0,"Assets_0_Q1_USD":727770000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":13857158.0,"AmortizationOfFinancingCostsAndDiscounts_1_Q1_USD":601000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":11262000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":11262000.0,"AdditionalPaidInCapital_0_Q1_USD":725465000.0,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q1_USD":-17285000.0,"AccruedProfessionalFeesCurrent_0_Q1_USD":1075000.0,"AccountsReceivableNetCurrent_0_Q1_USD":10608000.0,"AssetsCurrent_0_Q1_USD":702135000.0,"InventoryFinishedGoodsNetOfReserves_0_Q1_USD":968000.0,"DeferredCompensationShareBasedArrangementsLiabilityCurrent_0_Q1_USD":21151000.0,"DeferredRevenueNoncurrent_0_Q1_USD":451193000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":3916000.0,"IncreaseDecreaseInOtherOperatingLiabilities_1_Q1_USD":-1699000.0,"IncreaseDecreaseInOtherOperatingAssets_1_Q1_USD":-112000.0,"IncreaseDecreaseInOperatingLeaseLiability_1_Q1_USD":-425000.0,"IncreaseDecreaseInInventories_1_Q1_USD":1561000.0,"IncreaseDecreaseInDueToRelatedPartiesCurrent_1_Q1_USD":-504000.0,"IncreaseDecreaseInDeferredRevenue_1_Q1_USD":70491000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1_Q1_USD":-1674000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":7038000.0,"DeferredRevenueCurrent_0_Q1_USD":117231000.0,"IncreaseDecreaseInAccountsPayableTrade_1_Q1_USD":-8676000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-60749000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":0.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q1_USD":102200000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":17936000.0,"EffectiveIncomeTaxRateContinuingOperations_1_Q1_pure":-0.015,"EarningsPerShareDiluted_1_Q1_USD":-0.67,"EarningsPerShareBasic_1_Q1_USD":-0.67,"DueToRelatedPartiesNoncurrent_0_Q1_USD":358700000.0,"DueToRelatedPartiesCurrent_0_Q1_USD":39000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":911000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":91637151.0,"Ticker":"MYOV","CIK":"1679082","name":"MYOVANT SCIENCES LTD.","OfficialName":"Myovant Sciences Ltd. Common Shares","form":"10-Q","period":"20210630","fy":"2022.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1001965304.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20210728"}]